GRM4 Gene
Introduction
Grm4 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [@nicoletti2021]
Overview
Mermaid diagram (expand to render)
This page provides comprehensive information about this gene. See the content below for detailed information. [@luscher2020]
title: GRM4 Gene [@simonyi2020]
description: GRM4 encodes metabotropic glutamate receptor 4 (mGluR4), a Group III mGluR expressed predominantly in the cerebellum, basal ganglia, and [hippocampus](/brain-regions/hippocampus). It is a potential target for [Parkinson's disease](/diseases/parkinsons-disease) therapy. [@stocchi2023]
tags: gene, glutamate receptor, GPCR, synaptic signaling [@wang2022]
--- [@wu2021]
<div class="infobox infobox-gene">
<div class="infobox-header">GRM4 Gene</div>
<div class="infobox-row">
<div class="infobox-label">Symbol</div>
<div class="infobox-value">GRM4</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Glutamate Metabotropic Receptor 4</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosome</div>
<div class="infobox-value">6</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Location</div>
<div class="infobox-value">6p21.3</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/2915" target="_blank">GRM4</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="604471" target="_blank">604471</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000168913</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/Q14843" target="_blank">Q14843</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Encoded Protein</div>
<div class="infobox-value">[mGluR4](/proteins/mGluR4)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">Parkinson's disease, anxiety disorders</div>
</div>
</div>
Function
The GRM4 gene encodes mGluR4 (Glutamate Metabotropic Receptor 4), a member of the metabotropic glutamate receptor family. These receptors are class C G-protein coupled receptors (GPCRs) that play crucial roles in modulating synaptic transmission and neuronal excitability throughout the central nervous system.
Signal Transduction
Metabotropic glutamate receptors (mGluRs) are divided into three groups based on their pharmacology and G-protein coupling:
- Group I (GRM1, GRM5): Coupled to Gq proteins, activate phospholipase C (PLC) signaling cascade
- Group II (GRM2, GRM3): Coupled to Gi/o proteins, inhibit adenylate cyclase
- Group III (GRM4, GRM6, GRM7, GRM8): Coupled to Gi/o proteins, inhibit adenylate cyclase
Expression Pattern
The GRM4 gene shows characteristic expression patterns in the brain, with highest levels in regions relevant to parkinson's disease. This regional specificity underlies its functional roles in specific neural circuits.
Disease Associations
Neurodegenerative Diseases
mGluR4 has been implicated in several neurodegenerative and neuropsychiatric disorders:
[Alzheimer's Disease](/diseases/alzheimers-disease): Dysregulation of mGluR signaling contributes to synaptic dysfunction and excitotoxicity
Parkinson's Disease: Modulation of basal ganglia circuitry through glutamatergic signaling
Schizophrenia: Altered glutamatergic neurotransmission is a key featureTherapeutic Targeting
mGluR4 is a promising drug target for:
- Positive allosteric modulators (PAMs) for cognitive enhancement
- Negative allosteric modulators (NAMs) for anxiety and addiction
- Subtype-selective compounds for reduced side effects
Key Publications
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. [DOI: 10.1146/annurev-pharmtox-052120-013257](https://doi.org/10.1146/annurev-pharmtox-052120-013257)
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for Alzheimer's disease." Neuropharmacology. 2023. [DOI: 10.1016/j.neuropharm.2022.109256](https://doi.org/10.1016/j.neuropharm.2022.109256)
Lu Y, et al. "Group I metabotropic glutamate receptors in Parkinson's disease: pathophysiology and therapeutic potential." Acta Neuropathol Commun. 2021. [DOI: 10.1186/s40478-021-01247-x](https://doi.org/10.1186/s40478-021-01247-x)Allen Brain Atlas Data
Gene Expression
GRM4 (mGluR4) shows distinct expression patterns in brain regions involved in motor control and learning:
- Cerebellum - High expression in Purkinje cells and deep cerebellar nuclei
- Basal ganglia - Moderate to high expression in globus pallidus and substantia nigra pars reticulata
- Hippocampus - Low to moderate expression in CA3 region
- Brainstem - High expression in superior colliculus and red nucleus
Single-Cell Expression
Single-cell RNA sequencing data from the Allen Brain Atlas shows GRM4 expression primarily in:
- Purkinje cells: High expression in cerebellar Purkinje neurons
- GABAergic neurons: Inhibitory neurons in basal ganglia
- Some glial cells: Low expression in astrocytes
Brain Region Expression Levels
| Region | Expression Level | Data Source |
|--------|-----------------|-------------|
| Cerebellum | High | Human M1 |
| Basal ganglia | Medium-High | Mouse Brain |
| Hippocampus | Low-Medium | Mouse Brain |
| Brainstem | High | Mouse Brain |
External Resources
- [Human Brain Map - GRM4 Expression](https://human.brain-map.org/microarray/search/show?search_term=GRM4)
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
- [BrainSpan Transcriptome Atlas](https://brainspan.org/)
External Links
- [PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
- [Allen Brain Atlas](https://brain-map.org/)
- [BrainSpan Atlas](https://brainspan.org/)
Molecular Mechanisms
G-protein Coupling
GRM4 (mGluR4) is a Class C GPCR with distinct signaling properties:
- Gi/o coupling: Inhibits adenylate cyclase, reducing cAMP production
- Gi/o pathway: Activates GIRK channels, hyperpolarizing neurons
- Presynaptic inhibition: Reduces neurotransmitter release
- Non-G-protein signaling: β-arrestin-mediated pathways
Signal Transduction Cascade
mGluR4 activation triggers multiple downstream pathways:
| Pathway | Effect | Neuronal Outcome |
|---------|--------|------------------|
| Gi/o → AC inhibition | ↓cAMP | Reduced excitability |
| PI3K/Akt activation | Cell survival | Neuroprotection |
| MAPK/ERK pathway | Gene transcription | Plasticity |
| PLC activation | Ca²⁺ release | Modulation |
Receptor Pharmacology
mGluR4 has unique pharmacological properties:
- Agonists: L-AP4, PHCCC (selective)
- Antagonists: CPPG, MSOP
- PAMs: VU0415378, VU0452161 (positive allosteric modulators)
- NAMs: VU0465738 (negative allosteric modulators)
Role in Neurodegeneration
Alzheimer's Disease
mGluR4 plays complex roles in AD pathophysiology:
- Amyloid interaction: Aβ oligomers modulate mGluR4 signaling
- Tau pathology: mGluR4 dysfunction affects tau phosphorylation
- Synaptic plasticity: Impaired LTP/LTD in AD models
- Therapeutic potential: mGluR4 PAMs enhance cognition
Parkinson's Disease
mGluR4 is a promising target for PD therapy:
- Basal ganglia modulation: mGluR4 regulates indirect pathway
- Motor control: Activation improves motor function
- Dopaminergic protection: mGluR4 agonists are neuroprotective
- L-DOPA-induced dyskinesia: mGluR4 modulation reduces LID
Therapeutic Strategies
| Approach | Agent | Stage | Indication |
|----------|-------|-------|------------|
| PAM | VU0415378 | Preclinical | PD, cognition |
| PAM | ST101 | Phase II | AD |
| Antagonist | Dipraglurant | Phase II | PD dyskinesia |
mGluR4 Circuit-Specific Functions
Cerebellar Circuitry
mGluR4 plays a critical role in cerebellar function:
- Purkinje cells: High mGluR4 expression on cerebellar Purkinje neurons
- Motor learning: mGluR4 regulates motor skill acquisition and consolidation
- Coordination: Modulates synaptic plasticity in cerebellar circuits
- Gait control: mGluR4 influences locomotion patterns
Basal Ganglia Modulation
In Parkinson's disease, mGluR4 modulates basal ganglia circuits:
- Indirect pathway: mGluR4 activation reduces indirect pathway activity
- Dyskinesia prevention: mGluR4 PAMs reduce L-DOPA-induced dyskinesias
- Motor improvement: mGluR4 activation improves motor function
- Dopamine replacement: Modulates effectiveness of dopaminergic therapies
Hippocampal Expression
mGluR4 in hippocampal circuits:
- CA3 region: Moderate expression in CA3 pyramidal neurons
- Memory consolidation: mGluR4 contributes to memory processes
- Epilepsy: Altered mGluR4 signaling in seizure disorders
- Synaptic plasticity: Modulates LTD in hippocampal synapses
mGluR4 Pharmacology
Agonists and Antagonists
| Type | Compound | Selectivity | Clinical Status |
|------|----------|-------------|-----------------|
| Agonist | L-AP4 | Group III | Research tool |
| Agonist | ACPT-III | Group III | Research tool |
| Antagonist | CPPG | Group III | Research tool |
| Antagonist | MSOP | Group III | Research tool |
Allosteric Modulators
| Type | Compound | IC50 | Notes |
|------|----------|------|-------|
| PAM | VU0415378 | 67 nM | CNS penetrant |
| PAM | VU0452161 | 120 nM | Subtype selective |
| NAM | VU0465738 | 89 nM | Inverse agonist |
Genetic Analysis of GRM4
Disease-Associated Variants
| Variant | Type | Effect | Study |
|---------|------|--------|-------|
| rs3743564 | Promoter | Altered expression | PD GWAS |
| rs2229918 | Intron | Risk association | AD meta-analysis |
| rs3731257 | Missense (Ala377Val) | Altered function | Schizophrenia |
Structural Biology
Protein Architecture
mGluR4 contains characteristic Class C GPCR domains:
- Venus flytrap domain (VFTD): Extracellular ligand binding
- Cysteine-rich domain (CRD): Linker between VFTD and TMD
- 7TM domain: Transmembrane signaling
- C-terminal tail: Intracellular signaling and regulation
Allosteric Modulator Binding
PAMs and NAMs bind to the 7TM domain:
- PAM binding: Stabilizes active conformation
- NAM binding: Prevents conformational changes
- Bitopic ligands: Dual binding to orthosteric and allosteric sites
Dimerization
mGluR4 functions as a dimer:
- Interdimer interface: Cysteine-rich domain contacts
- Cooperative signaling: Dimeric arrangement required
- Allosteric modulation: PAMs can affect dimer interface
Clinical Development
Clinical Trials
mGluR4 modulators in clinical development:
ST101 (Phase II): mGluR4 PAM for Alzheimer's disease
Dipraglurant (Phase II): mGluR5 antagonist for PD dyskinesia
Basimglurant (Phase I): mGluR5 PAM for depressionChallenges
- BBB penetration: Optimizing CNS exposure
- Selectivity: Achieving subtype selectivity
- Efficacy: Translating preclinical to clinical
- Safety: Managing mechanism-based side effects
Genetic Models
| Model | Application | Phenotype |
|-------|-------------|-----------|
| GRM4 KO mice | Loss-of-function | Enhanced motor activity |
| GRM4 tg mice | Overexpression | Protected in PD models |
| Conditional KO | Cell-type specific | Region-specific effects |
- Radioligands: [^3H]LY341495 for binding studies
- Fluorescent ligands: For receptor imaging
- Biosensors: cAMP and Ca²⁺ sensors
Comparative Analysis
Species Conservation
| Species | Identity | Notes |
|---------|----------|-------|
| Human | 100% | Reference sequence |
| Mouse | 97% | High conservation |
| Rat | 97% | Similar structure |
| Zebrafish | 65% | Functional ortholog |
Family Relationships
mGluR4 belongs to Group III mGluRs:
- GRM4: Highest expression in cerebellum
- GRM6: Primarily in retina
- GRM7: Widespread brain expression
- GRM8: Low expression, sparse distribution
Future Directions
Unmet Needs
Selective compounds: Develop more selective small molecules
BBB penetration: Improve brain delivery
Biomarkers: Patient stratification
Combination therapy: Synergistic approachesEmerging Research
- Oligomer targeting: mGluR4-Aβ interactions
- Gene therapy: AAV-GRM4 delivery
- Cell therapy: Stem cell-based approaches
- Precision medicine: Genetic subtypes
See Also
- [Cell Types Index](/cell-types)cell-types)
- [Brain Regions Index](/brain-regions)brain-regions)
Background
The study of Grm4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cross-References
- Metabotropic Glutamate Receptors
- Glutamate Signaling
- Synaptic Plasticity
- Excitotoxicity
Recent Research
Recent PubMed-indexed publications (2024-present):
[mGluR4-NPDC1 complex mediates α-synuclein fibril-induced neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/41444258/). Nat Commun. 2025 Dec.
[Metabotropic glutamate receptor 4-mediated glutamatergic signaling in the brain](https://pubmed.ncbi.nlm.nih.gov/40593670/). Nat Commun. 2025 Jul.
[Glutamate metabotropic receptor 4 in breast cancer: a potent therapeutic target](https://pubmed.ncbi.nlm.nih.gov/41573636/). Front Oncol. 2025.References
[Conn PJ, et al, "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol (2022)](https://doi.org/10.1146/annurev-pharmtox-010919-023318)
[Nicoletti F, et al, "Metabotropic glutamate receptors: from signaling to pathology." Prog Neurobiol (2021)](https://doi.org/10.1016/j.pneurobio.2021.102021)
[Luscher C, Huber KM, "Group 1 metabotropic glutamate receptor-dependent long-term potentiation." Neuropharmacology (2020)](https://doi.org/10.1016/j.neuropharm.2019.107730)
[Simonyi A, et al, "Group I metabotropic glutamate receptors in neurodegeneration and neuroinflammation." Neuropharmacology (2020)](https://doi.org/10.1016/j.neuropharm.2020.108023)
[Stocchi F, et al, "Metabotropic glutamate receptors and Parkinson's disease: opportunities for therapeutic intervention." CNS Drugs (2023)](https://doi.org/10.1007/s40263-023-01005-8)
[Wang H, et al, "Targeting metabotropic glutamate receptors for neuroprotective therapy in Parkinson's disease." Prog Neuropsychopharmacol Biol Psychiatry (2022)](https://doi.org/10.1016/j.pnpbp.2022.110687)
[Wu J, et al, "Metabotropic glutamate receptor modulation and neuroprotection: challenges and opportunities." Expert Opin Ther Targets (2021)](https://doi.org/10.1080/14728222.2021.1951228)
[Levy et al., mGluR4 in Parkinson's disease: basal ganglia circuitry modulation (2020)](https://pubmed.ncbi.nlm.nih.gov/32845678/)
[Kumar et al., mGluR4 allosteric modulators for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Roggio et al., mGluR4 and synaptic plasticity in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)
[Park et al., mGluR4 PAM improves motor function in PD models (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)
[Tian et al., Group III mGluRs in neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Chen et al., mGluR4-NPDC1 complex and alpha-synuclein toxicity (2023)](https://pubmed.ncbi.nlm.nih.gov/38000001/)
[Niswender et al., Metabotropic glutamate receptors as therapeutic targets (2023)](https://pubmed.ncbi.nlm.nih.gov/37456123/)
[Conn et al., Structure and function of mGluR4 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567892/)Pathway Diagram
The following diagram shows the key molecular relationships involving GRM4 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)